Bristol-Myers Squibb Co news

   Watch this stock
Showing stories 1 - 10 of about 163   

Articles published

BMY 68.30 -0.59 (-0.86%)
price chart
Bristol-Myers Squibb Co (NYSE:BMY) a Buy: BMO Capital
In a research note issued to investors, Alex Arfaei at BMO Capital Reiterated their Buy rating on Bristol-Myers Squibb Co (NASDAQ:BMY).
Drug Manufacture Most Active Stocks: Pfizer Inc. (NYSE:PFE), Bristol-Myers ...  StreetWise Report
Jacobs Awarded Additional Contract from Bristol-Myers Squibb  MarketWatch
Bristol-Myers Squibb Receives Positive CHMP Opinion in the European Union ...
PRINCETON, N.J., May 22, 2015 (BUSINESS WIRE) -- Bristol-Myers Squibb Company BMY, -0.78% today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive ...
Bristol-Myers Squibb Company (press release)
Stock Analysis on Bristol-Myers Squibb Co (NYSE:BMY)
[Business Wire] Bristol-Myers Squibb Co (NYSE:BMY)(TREND ANALYSIS) will present at the Bank of America Merrill Lynch 2015 Health Care Conference on Tuesday, May 12, 2015, in Las Vegas.
Bristol-Myers Squibb Announces the Early Results of its Cash Tender Offer ...  MarketWatch
Cookies on Pharmiweb.Com (press release)
Afternoon Movers: MagneGas Corporation (MNGA), Bristol-Myers Squibb ...
Bristol-Myers Squibb Company, declared that the U.S. Food and Drug Administration (FDA) has amended a formerly granted Breakthrough Therapy Designation for the investigational daclatasvir and sofosbuvir combination for use in hepatitis C (HCV) ...
Bristol-Myers Squibb Co. (BMY) Pops 2.89% for May 08
One of the S&P 500's big winners for Friday May 08 was Bristol-Myers Squibb Co. (BMY) as the company's stock climbed 2.89% to $66.93 on volume of 5.46 million shares.
Bristol-Myers Squibb Pins Its Hopes On Eliquis And Immuno-Oncology  Trefis
Closing Bell Reports: Bristol-Myers Squibb Company (BMY), Exelon Corporation ...  WallStreet Scope
Bristol-Myers Squibb Co And AbbVie Inc Drug Delays Multiple Myeloma ...
An experimental cancer drug being developed by Bristol-Myers Squibb Co (NYSE:BMY) in collaboration with AbbVie Inc (NYSE:ABBV), when added to an earlier treatment for multiple myeloma, has been shown to have delayed the progression of the disease ...
Bristol-Myers-AbbVie Drug Improves Remission in Blood Cancer  Bloomberg
Bristol and AbbVie Drug Delayed Blood Cancer Progression  Nasdaq
Bristol-Myers Squibb Co CM-017 Shows Positive OS; Elotuzumab Data Solid In ...
In a report published on Friday, SunTrust Robinson Humphrey expressed that Bristol-Myers Squibb Co's (NYSE:BMY) CheckMate-017 showed positive overall survival (OS), while elotuzumab data was also solid in multiple myeloma.
Earnings Buzz: Pfizer Inc (PFE), Merck & Co Inc (MRK), Bristol-Myers Squibb Co ...
Earnings season continues in full swing this week as pharmaceutical giants Pfizer Inc., Merck & Co. Inc. and Bristol-Myers Squibb Co. are among 40 Standard & Poor's 500 companies reporting quarterly results Tuesday. Of the S&P 500 companies that have ...
Option Volume Soars on Bristol-Myers Squibb Company, Merck & Co., Inc.  Schaeffers Research (blog)
Pfizer, Merck and Bristol-Myers Squibb Report Solid Results  Wall Street Journal
New CEO Caforio, a doctor, takes reins after drugmaker Bristol-Myers Squibb's ...
TRENTON, N.J. - Drugmaker Bristol-Myers Squibb Co. has a new leader, Dr. Giovanni Caforio, who became CEO as the company's annual meeting in Plainsboro, New Jersey, ended Tuesday.
New CEO takes over evolving drugmaker Bristol-Myers Squibb  Washington Times
Merck & Co. (NYSE:MRK) and Bristol-Myers Squibb (NYSE:BMY)Taking on the ...
Last year, both Merck & Co. (NYSE:MRK) and Bristol-Myers Squibb (NYSE:BMY) entered the era of a new technology with their Keytruda and Opdivo inhibitors respectively.